Abstract
Background Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Both janus kinase (JAK) inhibitor, baricitinib, and dexamethasone demonstrated the reduction of mortality. In this matched control study we compared dexamethasone to another JAK inhibitor, ruxolitinib.
Methods The study included 146 hospitalized patients with COVID-19 and oxygen support requirement. The control group was selected 1:1 from 1355 dexamethasone-treated patients and was matched by 29 clinical and laboratory parameters predicting survival.
Results Ruxolitinib treatment in the general cohort of patients was associated with equivalent to dexamethasone mortality rate: 9,6% (95% CI 4,6-14,6%) vs 13,0% (95% CI 7,5-18,5%, superiority p=0.35, non-inferiority p=0.0137), respectively. Time to discharge without oxygen support requirement was also not different between these groups: 13 vs 11 days (p=0.13). Subgroup analysis without adjustment for multiple comparisons demonstrated reduced mortality in ruxolitnib-treated patients with febrile fever (OR 0.33, 95%CI 0.11-1.00). Except higher incidence of grade 1 thrombocytopenia (37% vs 23%, p=0.042), ruxolitinib therapy was associated with better safety profile due to reduced rate of severe cardiovascular adverse events (6.8% vs 15%, p=0.025).
Conclusions Ruxolitinib may be an alternative anti-cytokine therapy with comparable efficacy in patients with potential risks of steroid administration. Patients with febrile fever at admission may benefit from ruxolitinib administration.
Funding Ruxolitinib was obtained from Novartis through Managed Access Program (MAP).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04337359
Funding Statement
Ruxolitinib was obtained from Novartis through Managed Access Program (MAP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB decision: The study protocol was approved by the biomedical ethics committee of I.P. Pavlov First Saint Petersburg State Medical University. IRB members: Edwin E. Zvartau, First Saint Petersburg State Pavlov Medical University, Valdman Institute of Pharmacology, head of IRB Vasiliy I. Trofimov, First Saint Petersburg State Pavlov Medical University, deputy head of IRB Marina V. Cherevkova, First Saint Petersburg State Pavlov Medical University, executive secretary Boris V. Afanasiev, First Saint Petersburg State Pavlov Medical University, committee member Svetlana V. Alimovna, First Saint Petersburg State Pavlov Medical University, committee member Tatiana N. Ketova, First Saint Petersburg State Pavlov Medical University, committee member Natalia V. Egorova, First Saint Petersburg State Pavlov Medical University, committee member Ashot M. Esayan, First Saint Petersburg State Pavlov Medical University, committee member Sergey M. Lazarev, First Saint Petersburg State Pavlov Medical University, committee member Alexey Y. Malikov, First Saint Petersburg State Pavlov Medical University, committee member Tatyana G. Medvedeva, First Saint Petersburg State Pavlov Medical University, committee member Yana I. Startseva, First Saint Petersburg State Pavlov Medical University, committee member Andrey Y. Cibin, First Saint Petersburg State Pavlov Medical University, committee member Yulia V. Emanuel, First Saint Petersburg State Pavlov Medical University, committee member
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No applicable
